Trial reportScientific reports2025
Investigating the feasibility and safety of transcranial infraslow gray noise stimulation as a potential treatment for generalized anxiety disorder.
Trial report in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety is a beneficial behavior that assists survival, although when high levels of anxiety persist it can hinder normal functioning. Despite numerous treatment options most individuals with Generalized Anxiety Disorder (GAD) continue to suffer from the disorder. A novel neuromodulatory treatment that safely and non-invasively alters pathological neural circuitry associated with GAD is required. Therefore, this study investigates the feasibility, safety, and effect of a new innovative High-Definition Transcranial Infraslow Gray Noise Stimulation (HD-tIGNS) targeting the anxiety network in people with GAD, in a delayed-start double-blinded randomized sham-controlled pilot trial (N = 22). HD-tIGNS was applied three times per week for three [delayed-start (following 3-weeks of actisham)], or six weeks (early-start). Anxiety questionnaires and electroencephalography were taken at baseline, mid-treatment, and post-treatment. On average, six participants were recruited per month with a mean treatment adherence of 99.5%, and an 8.3% dropout rate of enrolled participants. Clinically meaningful changes in GAD-7 were observed in 45% (early-start group) and 36% (delayed-start group) of participants following 6-weeks and 3-weeks of intervention respectively. No significant differences in brain activity or functional connectivity were observed. This study provides evidence supporting HD-tIGNS as a safe and feasible treatment approach for GAD, however future research should consider alternate network targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.